Profile data is unavailable for this security.
About the company
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.
- Revenue in USD (TTM)3.92m
- Net income in USD-178.12m
- Incorporated2015
- Employees124.00
- LocationIDEAYA Biosciences Inc7000 SHORELINE CT, SUITE 350SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 443-6209
- Fax+1 (302) 655-5049
- Websitehttps://www.ideayabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beam Therapeutics Inc | 349.64m | -143.59m | 2.07bn | 436.00 | -- | 2.61 | -- | 5.93 | -1.72 | -1.72 | 4.27 | 9.58 | 0.284 | -- | -- | 801,933.50 | -11.67 | -24.54 | -13.84 | -29.26 | -- | -- | -41.07 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Wave Life Sciences Ltd | 53.61m | -142.52m | 2.08bn | 266.00 | -- | 14.95 | -- | 38.76 | -1.11 | -1.11 | 0.427 | 1.01 | 0.192 | -- | 15.32 | 201,541.40 | -51.04 | -56.98 | -99.07 | -102.38 | -- | -- | -265.84 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Mirum Pharmaceuticals Inc | 307.03m | -99.81m | 2.13bn | 311.00 | -- | 9.25 | -- | 6.95 | -2.12 | -2.12 | 6.51 | 4.84 | 0.4657 | 3.83 | 5.28 | 1,162,985.00 | -15.14 | -38.93 | -17.70 | -44.88 | 72.68 | -- | -32.51 | -190.71 | 3.15 | -- | 0.5701 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Azenta Inc | 656.32m | -164.17m | 2.21bn | 3.30k | -- | 1.16 | -- | 3.37 | -2.97 | -2.97 | 12.31 | 38.82 | 0.2633 | 3.23 | 3.71 | -- | -6.59 | -2.07 | -7.18 | -2.31 | 40.13 | 43.11 | -25.01 | -8.76 | 3.50 | -- | -- | -- | -1.32 | -3.41 | -1,174.32 | -- | -- | -- |
| CG Oncology Inc | 684.00k | -78.29m | 2.25bn | 61.00 | -- | 4.21 | -- | 3,282.26 | -1.19 | -1.19 | 0.0104 | 7.95 | 0.0018 | -- | 9.91 | 11,213.12 | -18.93 | -- | -19.63 | -- | -- | -- | -10,578.22 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Keros Therapeutics Inc | 651.00k | -181.57m | 2.27bn | 160.00 | -- | 4.12 | -- | 3,479.53 | -5.21 | -5.21 | 0.0187 | 13.57 | 0.0014 | -- | -- | 4,786.77 | -40.10 | -35.95 | -42.23 | -38.07 | -- | -- | -27,890.94 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Akero Therapeutics Inc | 0.00 | -237.22m | 2.28bn | 60.00 | -- | 3.09 | -- | -- | -3.75 | -3.75 | 0.00 | 10.61 | 0.00 | -- | -- | 0.00 | -32.66 | -37.73 | -34.35 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0454 | -- | -- | -- | -35.46 | -- | -- | -- |
| Arrowhead Pharmaceuticals Inc | 19.65m | -538.64m | 2.30bn | 525.00 | -- | 6.97 | -- | 117.30 | -4.65 | -4.65 | 0.1701 | 2.66 | 0.0234 | -- | -- | 37,424.76 | -65.18 | -20.02 | -73.62 | -24.65 | -- | -- | -2,785.85 | -61.79 | -- | -154.93 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Ideaya Biosciences Inc | 3.92m | -178.12m | 2.32bn | 124.00 | -- | 1.96 | -- | 590.39 | -2.32 | -2.32 | 0.0515 | 13.67 | 0.0044 | -- | 1.17 | 31,629.03 | -20.09 | -19.17 | -20.87 | -21.05 | -- | -- | -4,541.56 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -76.34m | 2.33bn | 50.00 | -- | 8.48 | -- | -- | -2.24 | -2.24 | 0.00 | 7.05 | 0.00 | -- | -- | 0.00 | -42.91 | -- | -46.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Belite Bio Inc (ADR) | 0.00 | -33.03m | 2.46bn | 20.00 | -- | 22.08 | -- | -- | -1.11 | -1.11 | 0.00 | 3.63 | 0.00 | -- | -- | 0.00 | -38.10 | -- | -38.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Geron Corp | 29.48m | -201.19m | 2.46bn | 141.00 | -- | 8.40 | -- | 83.46 | -0.3221 | -0.3221 | 0.0469 | 0.4846 | 0.0687 | -- | 1.31 | 209,078.00 | -46.90 | -51.32 | -63.81 | -64.90 | 97.29 | -- | -682.47 | -19,949.13 | 2.74 | -- | 0.2229 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Soleno Therapeutics Inc | 0.00 | -131.16m | 2.49bn | 33.00 | -- | 8.96 | -- | -- | -3.31 | -3.31 | 0.00 | 6.45 | 0.00 | -- | -- | 0.00 | -72.82 | -53.90 | -82.94 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Apogee Therapeutics Inc | 0.00 | -146.66m | 2.54bn | 91.00 | -- | 3.37 | -- | -- | -2.67 | -2.67 | 0.00 | 12.91 | 0.00 | -- | -- | 0.00 | -24.39 | -- | -25.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Iovance Biotherapeutics Inc | 90.86m | -410.00m | 2.61bn | 557.00 | -- | 3.37 | -- | 28.68 | -1.50 | -1.50 | 0.3273 | 2.54 | 0.0986 | 3.24 | -- | 163,120.30 | -44.48 | -51.47 | -50.17 | -57.56 | 14.75 | -- | -451.25 | -137,873.80 | 3.90 | -- | 0.0013 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
Data as of Nov 25 2024. Currency figures normalised to IDEAYA Biosciences Inc's reporting currency: US Dollar USD
56.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 12.64m | 14.96% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.45m | 7.63% |
| Federated Global Investment Management Corp.as of 30 Sep 2024 | 5.21m | 6.17% |
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 5.12m | 6.07% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.58m | 5.42% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 3.92m | 4.65% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 3.32m | 3.93% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2024 | 2.57m | 3.04% |
| Logos Global Management LPas of 30 Sep 2024 | 2.10m | 2.49% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.95m | 2.30% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
